Literature DB >> 19885117

Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes.

Poul Strange1.   

Abstract

BACKGROUND: Until recently, titration of insulin in type 2 diabetes clinical trials was typically left up to the investigator's discretion with a simple statement of the target ranges for glucose. In type 2 diabetes trials the average glycemic control achieved was usually less than desirable. Since then a number of trials have been conducted and reported utilizing various algorithms under various conditions. The objective of this article is to provide a review of the evidence to date.
METHODS: In addition to studies already identified through work in the area, the literature was searched using PubMed with the search words "insulin and titration" and subsequently "insulin and algorithm" from which studies starting insulin therapy using insulin titration algorithms in type 2 diabetes were selected.
RESULTS: The different algorithms and achieved results for glycemic control and hypoglycemia, as well as factors appearing to impact the results, are reviewed.
CONCLUSION: The recent introduction of rigorously implemented insulin titration algorithms when adding on basal insulin to oral drugs in inadequately treated type 2 diabetes patients has led to better average glycemic control with little risk of severe hypoglycemia, as long as the morning fasting plasma glucose target is not lower than 100 mg/dl. Insulin titration algorithms have undergone and continue evolution in the direction of increased patient control.

Entities:  

Keywords:  FPG; NPH; algorithm; basal; detemir; fasting glucose; glargine; insulin; severe hypoglycemia; titration

Year:  2007        PMID: 19885117      PMCID: PMC2769634          DOI: 10.1177/193229680700100412

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  26 in total

1.  Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

Authors:  H Yki-Järvinen; A Dressler; M Ziemen
Journal:  Diabetes Care       Date:  2000-08       Impact factor: 19.112

2.  Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea.

Authors:  M Riddle; J Hart; P Bingham; C Garrison; P McDaniel
Journal:  Am J Med Sci       Date:  1992-03       Impact factor: 2.378

3.  Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial.

Authors:  Laurence Kennedy; William H Herman; Poul Strange; Anthony Harris
Journal:  Diabetes Care       Date:  2006-01       Impact factor: 19.112

4.  Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry.

Authors:  Andrew J Karter; Howard H Moffet; Jennifer Liu; Melissa M Parker; Ameena T Ahmed; Assiamira Ferrara; Joe V Selby
Journal:  Am J Manag Care       Date:  2005-04       Impact factor: 2.229

5.  Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Authors:  Julio Rosenstock; Danny Sugimoto; Poul Strange; John A Stewart; Erika Soltes-Rak; George Dailey
Journal:  Diabetes Care       Date:  2006-03       Impact factor: 19.112

6.  Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups.

Authors:  Hannele Yki-Järvinen; Leena Juurinen; Michael Alvarsson; Tord Bystedt; Ian Caldwell; Melanie Davies; Sanni Lahdenperä; Gil Nijpels; Markku Vähätalo
Journal:  Diabetes Care       Date:  2007-03-23       Impact factor: 19.112

7.  Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

Authors:  Philip Raskin; Elsie Allen; Priscilla Hollander; Andrew Lewin; Robert A Gabbay; Peter Hu; Bruce Bode; Alan Garber
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

8.  Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

Authors:  Robert J Heine; Luc F Van Gaal; Don Johns; Michael J Mihm; Mario H Widel; Robert G Brodows
Journal:  Ann Intern Med       Date:  2005-10-18       Impact factor: 25.391

9.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

Authors:  Matthew C Riddle; Julio Rosenstock; John Gerich
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

10.  Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.

Authors:  M C Riddle; J Schneider
Journal:  Diabetes Care       Date:  1998-07       Impact factor: 19.112

View more
  27 in total

1.  Titrating beyond glycemic goal: "post-glycemic target phenomenon".

Authors:  Allen B King; Dawn Clark; Gary S Wolfe
Journal:  J Diabetes Sci Technol       Date:  2013-07-01

2.  Misled by the Morning "Fasting" Plasma Glucose.

Authors:  Allen B King
Journal:  J Diabetes Sci Technol       Date:  2015-05-13

3.  Evaluation of a Remote Monitoring System for Diabetes Control.

Authors:  Bonnie Katalenich; Lizheng Shi; Shuqian Liu; Hui Shao; Roberta McDuffie; Gandahari Carpio; Tina Thethi; Vivian Fonseca
Journal:  Clin Ther       Date:  2015-04-11       Impact factor: 3.393

4.  Basal-prandial insulin delivery in type 2 diabetes mellitus via the V-Go: a novel continuous subcutaneous infusion device.

Authors:  Christoph Kapitza; Seymour Fein; Lutz Heinemann; Debra Schleusener; Steven Levesque; Poul Strange
Journal:  J Diabetes Sci Technol       Date:  2008-01

5.  A novel approach to optimise glycaemic control in insulin users.

Authors:  Eran Bashan; Roy Harper; Yixi Bi; Israel Hodish
Journal:  BMJ Case Rep       Date:  2015-07-31

Review 6.  Common standards of basal insulin titration in type 2 diabetes.

Authors:  Sabine Arnolds; Tim Heise; Frank Flacke; Jochen Sieber
Journal:  J Diabetes Sci Technol       Date:  2013-05-01

7.  No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoring.

Authors:  Allen B King
Journal:  J Diabetes Sci Technol       Date:  2010-01-01

8.  Diabetes management: optimizing roles for nurses in insulin initiation.

Authors:  Bridget R Levich
Journal:  J Multidiscip Healthc       Date:  2011-02-20

9.  Uncovering undetected hypoglycemic events.

Authors:  Jeff Unger
Journal:  Diabetes Metab Syndr Obes       Date:  2012-03-08       Impact factor: 3.168

10.  Pharmacist intervention for glycaemic control in the community (the RxING study).

Authors:  Yazid N Al Hamarneh; Theresa Charrois; Richard Lewanczuk; Ross T Tsuyuki
Journal:  BMJ Open       Date:  2013-09-24       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.